Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
473 questions in 36 reviews · HIV/AIDS
current versionsNo studies 38 · 8%Ungraded 9 · 1.9%Very low 126 · 26.6%Low 127 · 26.8%Moderate 152 · 32.1%High 21 · 4.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Doctor vs nurse or clinical officer Lost to · HIV‐infected patients Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane | RR 0.3 [0.05, 1.94] | 2 studies · 39156 participants | Very low |
Doctor vs nurse or clinical officer Death or loss to · HIV‐infected patients Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane | RR 0.89 [0.79, 1.01] | 1 study · 2770 participants | High |
Doctor vs nurse or clinical officer Death or loss to · HIV‐infected patients Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane | RR 0.72 [0.48, 1.07] | 2 studies · 39160 participants | Very low |
Doctor vs nurse or clinical officer Death (RCTs) · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane | RR 0.89 [0.59, 1.32] | 2 studies · 4332 participants | Moderate |
Doctor vs nurse or clinical officer Death (Cohorts) · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane | RR 0.19 [0.05, 0.78] | 1 study · 2772 participants | Very low |
Doctor vs nurse or clinical officer Lost to · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane | RR 1.27 [0.92, 1.77] | 2 studies · 4332 participants | Moderate |
PRO 140 vs placebo Antiviral response: 0.5 mg/kg · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | OR 3 [0.11, 83.36] | 1 study · 19 participants | Very low |
PRO 140 vs placebo Individual nadir changes in HIV‐1 RNA level: 5 mg/kg · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | no estimate extracted | 2 studies · 40 participants | Very low |
PRO 140 vs placebo Individual nadir changes in HIV‐1 RNA level: 10 mg/kg · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | no estimate extracted | 1 study · 21 participants | Very low |
PRO 140 vs placebo Individual nadir changes in HIV‐1 RNA level: 162 mg weekly · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | no estimate extracted | 1 study · 21 participants | Very low |
PRO 140 vs placebo Individual nadir changes in HIV‐1 RNA level: 324 mg weekly · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | no estimate extracted | 1 study · 21 participants | Very low |
PRO 140 vs placebo Individual nadir changes in HIV‐1 RNA level: 324 mg biweekly · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
PRO 140 vs placebo Antiviral response: 2 mg/kg · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | OR 27.44 [1.25, 601.57] | 1 study · 19 participants | Very low |
PRO 140 vs placebo Antiviral response: 5 mg/kg · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | OR 439.09 [25.73, 7493.14] | 2 studies · 40 participants | Very low |
PRO 140 vs placebo Antiviral response: 10 mg/kg · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | OR 145.67 [5.3, 4004.91] | 1 study · 21 participants | Very low |
PRO 140 vs placebo Antiviral response: 162 mg weekly · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | OR 24.82 [1.17, 527.12] | 1 study · 21 participants | Very low |
PRO 140 vs placebo Antiviral response: 324 mg weekly · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | OR 147 [5.35, 4037.48] | 1 study · 21 participants | Very low |
PRO 140 vs placebo Antiviral response: 324 mg biweekly · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | OR 57 [2.59, 1253.22] | 1 study · 22 participants | Very low |
PRO 140 vs placebo Individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | no estimate extracted | 1 study · 19 participants | Very low |
PRO 140 vs placebo Individual nadir changes in HIV‐1 RNA level: 2 mg/kg · patients being treated for HIV infection Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection (2014) · Cochrane | no estimate extracted | 1 study · 19 participants | Very low |
Combination Chemotherapy + ART vs Single Agent Chemotherapy + ART Mortality · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 0.38 [0.24, 0.58] | 50 participants | Very low |
Chemotherapy + ART vs ART Mean CD4% Increase During Chemo · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | no estimate extracted | 48 participants | Very low |
Chemotherapy + ART vs ART Mortality · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 0.72 [0.37, 1.43] | 50 participants | Very low |
Chemotherapy + ART vs Chemotherapy Alone Complete Response to Tx · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 6.54 [1, 42.86] | 36 participants | Very low |
Chemotherapy + ART vs Chemotherapy Alone Complete/Partial Response to Tx · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 1.47 [0.87, 2.49] | 36 participants | Very low |
Chemotherapy + ART vs Chemotherapy Alone Complete Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 4.25 [0.7, 25.91] | 30 participants | Very low |
Chemotherapy + ART vs Chemotherapy Alone Complete/Partial Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 1.01 [0.81, 1.27] | 30 participants | Very low |
Chemotherapy + ART vs Chemotherapy Alone Mortality · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 0.46 [0.29, 0.73] | 98 participants | Very low |
Vincristine + ART vs Bleomycin + vincristine + ART Complete: Vincristine+ART vs Bleomycin+vincristine+ART · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 0.69 [0.33, 1.47] | 26 participants | Very low |
Vincristine + ART vs Bleomycin + vincristine + ART Complete/Partial: Vincristine+ART vs Bleomycin+vincristine+ART · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 0.79 [0.52, 1.2] | 26 participants | Very low |
ART alone vs Vincristine or Bleomycin Complete Response · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 1.2 [0.13, 11.43] | 24 participants | Very low |
ART alone vs Vincristine or Bleomycin Complete or Partial Response · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 0.2 [0.05, 0.79] | 24 participants | Very low |
Chemotherapy + ART vs ART Complete Response to Tx · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 1.57 [0.22, 11.34] | 89 participants | Very low |
Chemotherapy + ART vs ART Complete/Partial Response to Tx · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 5.75 [1.59, 20.73] | 39 participants | Very low |
Chemotherapy + ART vs ART Complete Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 0.84 [0.48, 1.48] | 26 participants | Very low |
Chemotherapy + ART vs ART Complete/Partial Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection Treatment of Kaposi sarcoma in children with HIV‐1 infection (2014) · Cochrane | RR 1.13 [0.67, 1.89] | 26 participants | Very low |
Hepatitis B vaccination vs placebo Hepatitis B Virus infection ‐ not measured · Persons with HIV infection Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection (2014) · Cochrane | no estimate extracted | NR | No studies |
Hepatitis B vaccination vs placebo Hepatitis B virus morbidity ‐ not measured · Persons with HIV infection Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection (2014) · Cochrane | no estimate extracted | NR | No studies |
Hepatitis B vaccination vs placebo Hepatitis B virus related mortality ‐ not measured · Persons with HIV infection Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection (2014) · Cochrane | no estimate extracted | NR | No studies |
Hepatitis B vaccination vs placebo All cause mortality ‐ not measured · Persons with HIV infection Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection (2014) · Cochrane | no estimate extracted | NR | No studies |
Hepatitis B vaccination vs placebo Hepatitis B antibody titre (IgG) · Persons with HIV infection Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection (2014) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Immunologic response to YF vaccine in HIV‐infected adults before HIV diagnosis, vs immunologic response to YF vaccine Immunogenicity: Adequate antibody response (NT ≥1:10), · Adults with HIV infection Yellow fever vaccine for patients with HIV infection (2014) · Cochrane | RR 0.91 [0.85, 0.98] | 1 study · 364 participants | Low |
Immunologic response to YF vaccine in HIV‐infected children vs immunologic response to YF vaccine Adequate antibody response (NT ≥1:10), · Children with HIV infection Yellow fever vaccine for patients with HIV infection (2014) · Cochrane | RR 0.23 [0.08, 0.64] | 1 study · 75 participants | Very low |
Immunologic response to YF vaccine in HIV‐infected adults vs immunologic response to YF vaccine Immunogenicity: Adequate antibody response (NT ≥1:10), · Adults with HIV infection Yellow fever vaccine for patients with HIV infection (2014) · Cochrane | RR 0.86 [0.77, 0.96] | 1 study · 144 participants | Very low |
Immunologic response to YF vaccine in HIV‐infected adults vs immunologic response to YF vaccine Duration: Adequate antibody response (NT ≥1:10), · Adults with HIV infection Yellow fever vaccine for patients with HIV infection (2014) · Cochrane | RR 0.88 [0.76, 1.02] | 1 study · 162 participants | Very low |
An extended NVP regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1week) HIV Transmission at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.56 [0.41, 0.76] | 1 study · 2019 participants | Moderate |
An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) Infant Mortality at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.66 [0.46, 0.96] | 1 study · 2000 participants | Moderate |
An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) HIV Transmission or Death at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.72 [0.57, 0.9] | 1 study · 2000 participants | High |
An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) HIV Transmission at 24 months among those uninfected at birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.65 [0.5, 0.85] | 1 study · 1123 participants | Moderate |
An extended NVP plus ZDV regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week) Infant Mortality at 24 months among those uninfected at birth · Breastfeeding infants of HIV‐infected mothers Antiretroviral interventions for preventing breast milk transmission of HIV (2014) · Cochrane | HR 0.73 [0.53, 1] | 1 study · 1207 participants | Moderate |